Wrt unblinding, we are not indubitably getting closer if the goal posts are continually being moved. Even now, I think it is a good bet that the SAP has not been completed and presented, given, handed over, submitted or whatever to the RAs. And if/when the 4 RAs give their blessings to the SAP is out of NWBO management's control. Furthermore, I don't think the remaining queries have all been cleared up. I think we are in for a long, long wait. Top line, I predict, will be announced in the 1/H of 2020 and they are pointing toward ASCO 2020 for the details. The ASM will be a repeat of last year's with Ike Esq preparing another questionnaire. LP will also ask for an increase in authorised shares. Warrants will expire worthless in April, 2020 unless holders pony up additional funds to roll over for another year.
Wrt a financing, we are indubitably getting closer each day. I doubt they sell the 17 acres anytime soon, so we are probably in for another, perhaps several, dilutions and debt financings highly favourable to LP, et al. Death by a thousand cuts.
SNO will come and go with still another meagre blinded update and nothing else followed by silence except for the announcement of the ASM and agenda---probably Feb. 2020.
What happens to the share price in the meantime? Indubitably, it drifts down to new lows and even single digits. The longer silence/waiting plays out, the more probable is the foregoing scenario. From such lows, even with highly favourable results, I don't believe the share price will explode a 1000%. It won't reach a dollar. Further, while I think that the results will be somewhat positive, they won't be stellar. Thus, we will be lucky if the share price reaches pre-ASCO 2019 levels. Approval will be a long way off and it is very possible that instead of an approval, the FDA will issue a CRL. If so, the end. Not a very promising outlook. JMHO.
